These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7105384)

  • 1. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.
    Van den Berg HW; Desai ZR; Wilson R; Kennedy G; Bridges JM; Shanks RG
    Cancer Chemother Pharmacol; 1982; 8(2):215-9. PubMed ID: 7105384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can severe vincristine neurotoxicity be prevented?
    Desai ZR; Van den Berg HW; Bridges JM; Shanks RG
    Cancer Chemother Pharmacol; 1982; 8(2):211-4. PubMed ID: 6125275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of vincristine sulfate in adult cancer patients.
    Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
    Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of vindesine and vincristine in humans.
    Owellen RJ; Root MA; Hains FO
    Cancer Res; 1977 Aug; 37(8 Pt 1):2603-7. PubMed ID: 872088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of vincristine sulfate in children.
    Sethi VS; Kimball JC
    Cancer Chemother Pharmacol; 1981; 6(2):111-5. PubMed ID: 7307229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.
    Sethi VS; Surratt P; Spurr CL
    Cancer Chemother Pharmacol; 1984; 12(1):31-5. PubMed ID: 6690071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of [3H]-vincristine in man.
    Bender RA; Castle MC; Margileth DA; Oliverio VT
    Clin Pharmacol Ther; 1977 Oct; 22(4):430-5. PubMed ID: 902455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans.
    Jackson DV; Sethi VS; Spurr CL; McWhorter JM
    Cancer Res; 1981 Apr; 41(4):1466-8. PubMed ID: 6260340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
    Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
    J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of vincristine infusion.
    Jackson DV; Sethi VS; Spurr CL; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Castle MC
    Cancer Treat Rep; 1981; 65(11-12):1043-8. PubMed ID: 7296550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer.
    Nelson RL
    Med Pediatr Oncol; 1982; 10(2):115-27. PubMed ID: 7070351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
    Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
    Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cirrhosis on the disposition and elimination of clindamycin.
    Avant GR; Schenker S; Alford RH
    Am J Dig Dis; 1975 Mar; 20(3):223-30. PubMed ID: 1168411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
    Kelkar MS; Saraf AP; Bakhle DS; Nazare V; Ajay S; Hegde S; Lal HM; Cooverji ND; Bruzzese T
    Int J Clin Pharmacol Res; 1998; 18(3):137-43. PubMed ID: 9825270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors.
    Villikka K; Kivistö KT; Mäenpää H; Joensuu H; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Dec; 66(6):589-93. PubMed ID: 10613614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: The relationship between serum alkaline phosphatase and vincristine neuropathy.
    Slevin ML; Harvey VJ; Wrigley PF
    Cancer Chemother Pharmacol; 1983; 10(2):140-1. PubMed ID: 6831628
    [No Abstract]   [Full Text] [Related]  

  • 17. Bleomycin clinical pharmacology by radioimmunoassay.
    Hall SW; Strong JE; Broughton A; Frazier ML; Benjamin RS
    Cancer Chemother Pharmacol; 1982; 9(1):22-5. PubMed ID: 6183016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of experimental extrahepatic cholestasis on absorption, distribution and elimination of digoxin].
    Wójcicki M
    Ann Acad Med Stetin; 1996; 42():51-65. PubMed ID: 9199126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents.
    Frost BM; Lönnerholm G; Koopmans P; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Uges DR; de Graaf SS
    Acta Paediatr; 2003 May; 92(5):551-7. PubMed ID: 12839283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of vincristine in cancer patients treated with nifedipine.
    Fedeli L; Colozza M; Boschetti E; Sabalich I; Aristei C; Guerciolini R; Del Favero A; Rossetti R; Tonato M; Rambotti P
    Cancer; 1989 Nov; 64(9):1805-11. PubMed ID: 2790693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.